Trials / Completed
CompletedNCT00002337
A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
A Phase I Safety and Tolerability Study of Four Doses of OPC-8212 (Vesnarinone) in Advanced HIV Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (planned)
- Sponsor
- Otsuka America Pharmaceutical · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
Detailed description
Fourteen patients per dose level receive vesnarinone at 1 of 4 doses for 12 weeks. At least seven patients at a given dose level must have completed 4 weeks of treatment before dose is escalated in subsequent patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vesnarinone |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00002337. Inclusion in this directory is not an endorsement.